<DOC>
	<DOCNO>NCT02417142</DOCNO>
	<brief_summary>This 24-week , randomize , double-blind , placebo-controlled trial exenatide weekly injection ( 2mg per dose ) adjunctive therapy 70 schizophrenia subject examine exenatide 's effect negative symptom cognition .</brief_summary>
	<brief_title>Exenatide Weekly Injections Adjunctive Treatment Patients With Schizophrenia</brief_title>
	<detailed_description>The specific aim include : Primary aim : 1 . Examine efficacy exenatide weekly injection improve negative symptom measure Scale Assessment Negative Symptoms ( SANS ) total score . Secondary aim : 1 . Examine efficacy exenatide improve cognition measure Measurement Treatment Research Improve Cognition Schizophrenia ( MATRICS ) Consensus Cognitive Battery ( MCCB ) composite score . Tertiary/Exploratory aim : 1 . Examine exenatide 's effect schizophrenia symptom measure Positive Negative Syndrome Scale ( PANSS ) total score . 2 . Examine efficacy exenatide improve social function measure Instrumental Activities Daily Living Scale ( IADL ) Heinrichs Carpenter Quality Life Scale ( QLS ) . 3 . Examine exenatide 's effect neuro-protection measure change hippocampal volume . 4 . Examine exenatide 's effect inflammatory marker include serum level high sensitivity C-reactive Protein ( CRP ) , Interleukin 6 ( IL-6 ) , tumor necrosis factor ( TNF-α ) . 5 . Examine potential moderator role baseline serum level C-reactive Protein ( CRP ) , Interleukin 6 ( IL-6 ) , tumor necrosis factor ( TNF-α ) , baseline hippocampal volume exenatide 's effect negative cognitive symptom . 6 . Examine potential mediator role change baseline serum level C-reactive Protein ( CRP ) , Interleukin 6 ( IL-6 ) , tumor necrosis factor ( TNF-α ) , hippocampal volume exenatide 's effect negative cognitive symptom . 7 . Examine efficacy exenatide reduce body weight improve glucose metabolism measure fasting plasma glucose HbA1c . 8 . Examine safety tolerability exenatide measure change side effect questionnaire ( SEQ , SEQabbrev ) , EKG vital sign</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>age 1865 year diagnosis schizophrenia schizoaffective disorder stable dose current antipsychotic drug least one month well establish compliance outpatient treatment per treat clinician 's judgment able complete cognitive assessment battery ( must English speaking ) Female subject eligible participate study nonchildbearing potential childbearing potential willing practice appropriate birth control method study inability provide inform consent current substance abuse psychiatrically unstable per treat clinician 's judgment significant medical illness include uncontrolled hypertension , diabetes , seizure disorder , severe cardiovascular , cerebrovascular , pulmonary , thyroid disease currently antiinflammatory immunosuppressant medication include oral steroid currently sulfonylurea drug ( e.g . glyburide ) history chronic infection ( include tuberculosis , HIV hepatitis ) , malignancy , organ transplantation , blood dyscrasia , central nervous system demyelinate disorder , know autoimmune inflammatory condition pregnant breastfeeding prisoner</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>